Usefulness of a single-assay chemiluminescence test (Tularaemia VIRCLIA IgG + IgM monotest) for the diagnosis of human tularemia. Comparison of five serological tests

  • África Cubero
  • Carlos Durántez
  • Ana Almaraz
  • Luis Fernández-Lago
  • María P. Gutiérrez
  • María J. Castro
  • Miguel A. Bratos
  • María Simarro
  • Gabriel A. March
  • Antonio Orduña
Original Article
  • 181 Downloads

Abstract

The aim of this work was to ascertain the usefulness of a new commercially-available single-assay chemiluminescence test (CHT) for the diagnosis of human tularemia (Tularaemia VIRCLIA IgG + IgM monotest, Vircell, Santa Fe, Granada, Spain). A total of 773 sera from 773 patients including 364 initial sera from patients with diagnosed tularemia, patients with suspected tularemia not confirmed (100), healthy people (152), patients with serology positive to Brucella (97), patients diagnosed with other infectious diseases (30), and patients diagnosed with autoimmune diseases (30) were included. All sera were tested by CHT, “in-house” microagglutination test (MAT), immunochromatographic test (ICT) (Virapid Tularaemia, Vircell, Santa Fe Granada, Spain), and “in-house” ELISA IgG, and ELISA IgM. Of the total initial sera, 334 (sensitivity 91.8%) were positive in the CHT, 332 (sensitivity 91.2%) in the MAT, 330 (sensitivity 90.7%) in the ICT, and 328 (sensitivity 90.1%) in the ELISA IgG and ELISA IgM tests. The specificity of the CHT was 96.7%; of the MAT, 100%; of the ICT, 98.7%; and of the ELISA IgG and ELISA IgM, 97.4%. In the group of patients with serology positive to Brucella, at least 12.4% of sera were positive in tularemia tests (12.4% in ELISA IgM, 13.4% in MAT, 14.4% in ICT, and 15.5% in CHT and ELISA IgG). In conclusion, CHT presents a sensitivity and specificity in early diagnosis of human tularemia, similar to MAT, ICT, and ELISA IgG and ELISA IgM. Its single assay design allows lower costs, especially in areas of low endemicity or inter-epidemic periods.

Notes

Acknowledgements

The authors wish to thank Prof. C. Nolan for collaborating with revising the English version.

Compliance with ethical standards

Conflicts of interest

We declare no conflicts of interest.

Ethical approval and informed consent

Written informed consent was taken by the participants and the study was approved by the Ethics Committee of the Valladolid Clinic University Hospital and the Faculty of Medicine of the University of Valladolid (reference CEIC-PI-16-478). All sera were anonymized in relation to patient data.

References

  1. 1.
    WHO (2007) WHO Guidelines on Tularaemia: epidemic and pandemic alert response. WHO Press, Geneva http://www.who.int/csr/resources/publications/WHO_CDS_EPR_2007_7.pdf Google Scholar
  2. 2.
    Rossow H, Ollgren J, Hytonen J, Rissanen H, Huitu O, Henttonen H, Kuusi M, Vapalahti O (2015) Incidence and seroprevalence of tularaemia in Finland, 1995 to 2013: regional epidemics with cyclic pattern. Euro Surveill 20(33):21209CrossRefPubMedGoogle Scholar
  3. 3.
    Desvars A, Furberg M, Hjertqvist M, Vidman L, Sjöstedt A, Rydén P, Johansson A (2015) Epidemiology and Ecology of Tularemia in Sweden, 1984–2012. Emerg Infect Dis J 21(1):32CrossRefGoogle Scholar
  4. 4.
    Mailles A, Vaillant V (2014) 10 years of surveillance of human tularaemia in France. Euro Surveill 19(45):20956CrossRefPubMedGoogle Scholar
  5. 5.
    Akalin H, Helvaci S, Gedikoglu S (2009) Re-emergence of tularemia in Turkey. Int J Infect Dis 13(5):547–551CrossRefPubMedGoogle Scholar
  6. 6.
    Ariza-Miguel J, Johansson A, Fernandez-Natal MI, Martinez-Nistal C, Orduna A, Rodriguez-Ferri EF, Hernandez M, Rodriguez-Lazaro D (2014) Molecular investigation of tularemia outbreaks, Spain, 1997-2008. Emerg Infect Dis 20(5):754–761CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Centro Nacional de Epidemiología (Instituto de Salud Carlos III) (1997) Brote de tularemia en Castilla y León. BES 5:249–252Google Scholar
  8. 8.
    Consejería de Sanidad (Junta de Castilla y León Spain) (2007) Informe sobre la situación epidemiológica de los casos de tularemia en Castilla y León. Año 2007 Consejería de Sanidad de la Junta de Castilla y León (Spain), Valladolid, Spain.http://www.saludcastillayleon.es/ciudadanos/es/enfermedades-problemas-salud/tularemia/vigilancia-epidemiologica-tularemia-castilla-leon2011
  9. 9.
    Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Layton M, Lillibridge SR, JE MD, Osterholm MT, O’Toole T, Parker G, Perl TM, Russell PK, Tonat K, for the Working Group on Civilian B (2001) Tularemia as a biological weapon: medical and public health management. JAMA 285(21):2763–2773CrossRefPubMedGoogle Scholar
  10. 10.
    Penn RL (2015) Francisella tularensis (Tularemia). In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases. Elsevier, Churchill Livingstone, Philadelphia, pp 2590–2602Google Scholar
  11. 11.
    Willke A, Meric M, Grunow R, Sayan M, Finke EJ, Splettstosser W, Seibold E, Erdogan S, Ergonul O, Yumuk Z, Gedikoglu S (2009) An outbreak of oropharyngeal tularaemia linked to natural spring water. J Med Microbiol 58(Pt 1):112–116CrossRefPubMedGoogle Scholar
  12. 12.
    Ellis J, Oyston PCF, Green M, Titball RW (2002) Tularemia. Clin Microbiol Rev 15(4):631–646CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Centers for Disease Control and Prevention (1997) Case definitions for infectious conditions under public health surveillance. MMWR 46:(No. RR-10)Google Scholar
  14. 14.
    Francis E, Evans AC (1926) Agglutination, cross-agglutination, and agglutinin absorption in tularemia. Public Health Rep 41:1273–1290CrossRefGoogle Scholar
  15. 15.
    Chaignat V, Djordjevic-Spasic M, Ruettger A, Otto P, Klimpel D, Muller W, Sachse K, Araj G, Diller R, Tomaso H (2014) Performance of seven serological assays for diagnosing tularemia. BMC Infect Dis 14:234CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kiliç S, Çelebi B, Yesilyurt M (2012) Evaluation of a commercial immunochromatographic assay for the serologic diagnosis of tularemia. Diagn Microbiol Infect Dis 74(1):1–5CrossRefPubMedGoogle Scholar
  17. 17.
    Garrote JI, Gutierrez MP, Izquierdo RL, Duenas MA, Zarzosa P, Canavate C, El Bali M, Almaraz A, Bratos MA, Berbel C, Rodriguez-Torres A, Domingo AO (2004) Seroepidemiologic study of Leishmania infantum infection in Castilla-Leon, Spain. Am J Trop Med Hyg 71(4):403–406PubMedGoogle Scholar
  18. 18.
    Brown SL, McKinney FT, Klein GC, Jones WL (1980) Evaluation of a safranin-O-stained antigen microagglutination test for francisella tularensis antibodies. J Clin Microbiol 11(2):146–148PubMedPubMedCentralGoogle Scholar
  19. 19.
    Sandstrom G, Sjostedt A, Johansson T, Kuoppa K, Williams JC (1992) Immunogenicity and toxicity of lipopolysaccharide from Francisella tularensis LVS. FEMS Microbiol Immunol 5(4):201–210CrossRefPubMedGoogle Scholar
  20. 20.
    Porsch-Ozcurumez M, Kischel N, Priebe H, Splettstosser W, Finke E-J, Grunow R (2004) Comparison of enzyme-linked immunosorbent assay, Western blotting, microagglutination, indirect immunofluorescence assay, and flow cytometry for serological diagnosis of tularemia. Clin Diagn Lab Immunol 11(6):1008–1015PubMedPubMedCentralGoogle Scholar
  21. 21.
    Splettstoesser W, Guglielmo-Viret V, Seibold E, Thullier P (2010) Evaluation of an immunochromatographic test for rapid and reliable serodiagnosis of human tularemia and detection of Francisella tularensis-specific antibodies in sera from different mammalian species. J Clin Microbiol 48(5):1629–1634CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Schmitt P, Splettstosser W, Porsch-Ozcurumez M, Finke EJ, Grunow R (2005) A novel screening ELISA and a confirmatory Western blot useful for diagnosis and epidemiological studies of tularemia. Epidemiol Infect 133(4):759–766CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Bevanger L, Maeland JA, Naess AI (1988) Agglutinins and antibodies to Francisella tularensis outer membrane antigens in the early diagnosis of disease during an outbreak of tularemia. J Clin Microbiol 26(3):433–437PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  • África Cubero
    • 1
  • Carlos Durántez
    • 1
  • Ana Almaraz
    • 1
  • Luis Fernández-Lago
    • 2
  • María P. Gutiérrez
    • 1
  • María J. Castro
    • 3
  • Miguel A. Bratos
    • 1
    • 4
  • María Simarro
    • 1
  • Gabriel A. March
    • 1
    • 4
  • Antonio Orduña
    • 1
    • 4
  1. 1.Department of Microbiology, Faculty of MedicineUniversity of ValladolidValladolidSpain
  2. 2.Department of MicrobiologyUniversity of SalamancaSalamancaSpain
  3. 3.Faculty of NurseryUniversity of ValladolidValladolidSpain
  4. 4.Service of MicrobiologyHospital Clínico UniversitarioValladolidSpain

Personalised recommendations